Trial Profile
The Effects of the Selective Serotonin Reuptake Inhibitor, Fluoxetine and/or DHEA, on Neuroendocrine, Autonomic Nervous System and Metabolic Counterregulatory Responses During Repeated Hypoglycemia in T1DM Individuals
Status:
Recruiting
Phase of Trial:
Phase 0
Latest Information Update: 13 Mar 2024
Price :
$35
*
At a glance
- Drugs Fluoxetine (Primary) ; Prasterone (Primary)
- Indications Depression
- Focus Pharmacodynamics
- 05 Mar 2024 Planned End Date changed from 15 Dec 2025 to 15 Dec 2026.
- 05 Mar 2024 Planned primary completion date changed from 15 Feb 2024 to 15 Feb 2025.
- 10 Feb 2023 Planned End Date changed from 15 Dec 2024 to 15 Dec 2025.